Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

1.

NRTI backbone in HIV treatment: will it remain relevant?

Tressler R, Godfrey C.

Drugs. 2012 Nov 12;72(16):2051-62. doi: 10.2165/11640830-000000000-00000.

PMID:
23083109
[PubMed - indexed for MEDLINE]
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
3.

Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF.

Curr Top Med Chem. 2004;4(9):895-919. Review.

PMID:
15134548
[PubMed - indexed for MEDLINE]
4.

Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Giaquinto C, Rampon O, Penazzato M, Fregonese F, De Rossi A, D'Elia R.

Clin Drug Investig. 2007;27(8):509-31. Review.

PMID:
17638393
[PubMed - indexed for MEDLINE]
5.

Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.

Bongiovanni M, Tordato F.

Curr Med Chem. 2006;13(23):2789-93. Review.

PMID:
17073629
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.

Imaz A, Llibre JM, Mora M, Mateo G, Camacho A, Blanco JR, Curran A, Santos JR, Caballero E, Bravo I, Gayá F, Domingo P, Rivero A, Falcó V, Clotet B, Ribera E.

J Antimicrob Chemother. 2011 Feb;66(2):358-62. doi: 10.1093/jac/dkq432. Epub 2010 Dec 14. Erratum in: J Antimicrob Chemother. 2011 Sep;66(9):2194.

PMID:
21172789
[PubMed - indexed for MEDLINE]
Free Article
7.

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

Wainberg MA, Sawyer JP, Montaner JS, Murphy RL, Kuritzkes DR, Raffi F.

Antivir Ther. 2005;10(1):13-28. Review.

PMID:
15751760
[PubMed - indexed for MEDLINE]
8.

Current and future antiretroviral treatment options in paediatric HIV infection.

Giaquinto C, Morelli E, Fregonese F, Rampon O, Penazzato M, de Rossi A, D'Elia R.

Clin Drug Investig. 2008;28(6):375-97. Review.

PMID:
18479179
[PubMed - indexed for MEDLINE]
9.

Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.

Joly V, Yeni P.

Antivir Ther. 2005;10(1):29-40. Review.

PMID:
15751761
[PubMed - indexed for MEDLINE]
10.

The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection.

Maddocks S, Dwyer D.

Paediatr Drugs. 2001;3(9):681-702. Review.

PMID:
11688599
[PubMed - indexed for MEDLINE]
11.

Apricitabine--a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs.

Cox S, Southby J.

Expert Opin Investig Drugs. 2009 Feb;18(2):199-209. doi: 10.1517/13543780802641337 . Review.

PMID:
19236266
[PubMed - indexed for MEDLINE]
12.

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S.

Antivir Chem Chemother. 2003 Jan;14(1):49-59.

PMID:
12790516
[PubMed - indexed for MEDLINE]
13.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.

AIDS. 2002 Oct 18;16(15):F41-7.

PMID:
12370521
[PubMed - indexed for MEDLINE]
14.

NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.

Joly V, Descamps D, Yeni P.

AIDS Rev. 2002 Jul-Sep;4(3):128-39. Review.

PMID:
12416447
[PubMed - indexed for MEDLINE]
15.

Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

Cihlar T, Ray AS.

Antiviral Res. 2010 Jan;85(1):39-58. doi: 10.1016/j.antiviral.2009.09.014. Epub 2009 Nov 1. Review.

PMID:
19887088
[PubMed - indexed for MEDLINE]
16.

Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.

Miller V, Larder BA.

Antivir Ther. 2001;6 Suppl 3:25-44. Review.

PMID:
11678471
[PubMed - indexed for MEDLINE]
17.

Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.

Antivir Ther. 2000 Mar;5(1):7-14.

PMID:
10846586
[PubMed - indexed for MEDLINE]
18.

An introduction to nucleoside and nucleotide analogues.

Squires KE.

Antivir Ther. 2001;6 Suppl 3:1-14. Review.

PMID:
11678469
[PubMed - indexed for MEDLINE]
19.

Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.

Balzarini J.

Biochem Pharmacol. 1999 Jul 1;58(1):1-27. Review.

PMID:
10403515
[PubMed - indexed for MEDLINE]
20.

Resistance issues with new nucleoside/nucleotide backbone options.

Wainberg MA, Turner D.

J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S36-43.

PMID:
15319668
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk